An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Phase 3 Completed 381 enrolled UCB Pharma

NaSingle-groupOpen-labelTreatment

Summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease

Timeline

Start: 2002-08
Primary completion: 2008-12
Completion: 2008-12

Publications

Giladi N, Boroojerdi B, Surmann E. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease. J Neural Transm (Vienna). 2013 Sep;120(9):1321-9. doi: 10.1007/s00702-013-1001-5. Epub 2013 Mar 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rotigotine	Unknown	2 mg	Other
Subject	Rotigotine	Unknown	4 mg	Other
Subject	Rotigotine	Unknown	6 mg	Other
Subject	Rotigotine	Unknown	8 mg	Other
Subject	Rotigotine	Unknown	10 mg	Other
Subject	Rotigotine	Unknown	12 mg	Other
Subject	Rotigotine	Unknown	14 mg	Other
Subject	Rotigotine	Unknown	16 mg	Other

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Summary

Timeline

Publications

Drugs

Indications